Prerpints.org logo
Preprint
Article

Patterns and Emerging Trends in Acute Poisoning with Substances of Abuse Used for Recreational Purposes in Adolescents: A Six-Year Multicentre Study

Altmetrics

Downloads

137

Views

49

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

19 July 2024

Posted:

22 July 2024

You are already at the latest version

Alerts
Abstract
This six-year multicentre study investigated acute intentional poisoning with substances of abuse in adolescents to identify changes and patterns in substance use. Data from 568 adolescents were collected from three paediatric poison centres in Romania between January 2017 and December 2022. The study analysed the epidemiological and sociodemographic characteristics of the adolescents, including age, gender, place of residence, history of substance abuse, psychiatric history, and history of institutionalized care. The findings revealed that cannabis and new psychoactive sub-stances (NPSs) are the most commonly implicated substances, each with distinct profiles among adolescents. Cannabis was involved in 45.6% of cases, with a significant association with urban residency. NPSs were identified as the second most prevalent substance, accounting for 38.9% of cases. These were more prevalent in rural areas and among patients with psychiatric disorders. Cannabis and NPSs were also the most commonly implicated substances in acute intentional poisoning cases with substances of abuse. These substances have distinct profiles among adolescents, including age, gender, residency area, history of substance abuse, psychiatric history, and institutional care. These findings underscore the necessity of targeted public health interventions and integrated care approaches to address substance use and related mental health issues in adolescents.
Keywords: 
Subject: Biology and Life Sciences  -   Toxicology

1. Introduction

The global problem of substance abuse poses a serious threat to public health and child safety, with significant consequences extending into adolescence. Any involvement in substance abuse at an early age can disrupt normal developmental processes and profoundly affect a child's future trajectory. Early exposure to substance abuse has been consistently associated with long-term physical, behavioural, social, and health risks [1,2,3,4].
Adolescence is a critical period characterized by vulnerability to substance use, which can lead to significant consequences such as the development of problematic substance use patterns, substance use disorders, and other psychiatric conditions such as depression, anxiety, and conduct disorder. In addition, substance use during this formative period can alter the brain development in the regions responsible for higher-order cognitive functions and inhibitory control, posing long-term cognitive challenges [5].
Adolescents make up 20% of the world's population and are particularly at risk of substance abuse [6]. Among 15-24-year-olds, about 18.2% (8.6 million) reported using cannabis in the last year, with 9.6% (4.5 million) using it in the last month [7]. Cannabis remains a significant problem, being the second most commonly reported substance in acute drug toxicity presentations in the Euro-DEN Plus hospital network in 2021; it was involved in 25% of such cases, often in combination with other substances [7].
In recent decades, new psychoactive substances (NPSs) have become a growing concern. By the end of 2022, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) was monitoring around 930 new psychoactive substances, of which 41 were reported in Europe for the first time in 2022 [7]. National estimates of last-year NPS use among young adults (aged 15-34) vary widely, from 0.1 % in Latvia to 5.1 % in Romania [7].
The prevalence of other illicit drugs is also striking. In the European Union, surveys suggest that almost 2.3 million young adults (aged 15-34) have used cocaine in the last year, and 1.3 million have used amphetamines [7]. In addition, 1.8 million young adults have reported using MDMA, with 2.0% of those aged 15-24 having used it in the past year [7].
Specifically in Romania, data from the Romanian Observatory of Drugs and Drug Addiction show that among 15-34-year-olds, rates of lifetime use, last-year use, and last-month use of any illicit drug are higher than those in the general population, at 16.9%, 10%, and 6.6%, respectively [8]. There has been a significant increase in last-month use, with a 1.4-fold increase compared with previous surveys [8]. Among 16-year-old students, lifetime use of any illicit drug is 9.5%, with 9% reporting use in the past year [8]. Notably, among those who have used cannabis in the last 12 months, more than one-quarter have also used ecstasy (29.3%) and cocaine (26.3%), and a significant proportion have also used amphetamines (20.7%), methamphetamines, or new psychoactive substances (around 16%) [8].
This six-year multicentre study aims to describe patterns and emerging trends in acute intentional poisoning that occur during recreational use of substances of abuse among adolescents, providing critical insights into the evolving landscape of adolescent substance use and its implications for public health strategies.

2. Materials and Methods

2.1. Study Design

This study employed an observational retrospective cohort analysis of data from three paediatric poison centres.
This study included patients under the age of 18 who were admitted to the hospital for acute intentional poisoning with substances of abuse between 1 January 2017 and 31 December 2022. Patients with acute intentional poisoning resulting from suicide attempts were not included in the study. This study adhered to the ethical principles outlined in the Declaration of Helsinki and was approved by the Ethics Committee of the hospital (Approval No. 11358, dated 18 March 2024). All guardians of the patients included provided informed consent for their participation.
This research analysed the epidemiological and sociodemographic characteristics of adolescents who had self-poisoned with substances of abuse.

2.2. Data Collection

Data were extracted from electronic health records using the International Classification of Diseases, 10th Revision, Australian Modification (ICD-10-AM) codes T40.0-T40.9 (narcotics and psychodysleptics), T42.3-T42.8 (antiepileptics, sedative–hypnotics, and antiparkinsonism drugs), and T43.0-T43.9 (psychotropic drugs), in addition to external cause codes X61-X64 (intentional self-poisoning). The variables collected included date of admission, age, sex, residential area, care in an institutional setting, psychiatric history, substance abuse history, circumstances of the poisoning event, and involved substances.

2.3. Statistical Analysis

Statistical analyses were performed using XL-STAT version 2023.5 (Addinsoft, Paris, France) and VassarStats version SCR-010263 (Vassar College, New York, USA). Continuous variables were expressed as means with standard deviations (SDs), while categorical data were presented as frequencies and percentages. Yates correction of the chi-square test and standardized residuals were used to assess the relationships between categorical variables [9]. One-way ANOVA was conducted to compare the median age values across different subgroups. The temporal trends of frequencies were assessed using the Cochran–Armitage test [10,11]. A p-value of <0.05 was considered statistically significant.

3. Results

3.1. Patient Characteristics and Poisoning Circumstances

The cohort comprised 568 adolescents who presented with acute intentional poisoning with substances of abuse during the study period.
The incriminated substances were cannabis (45.6%, n=259), NPSs (38.9%, n=221), benzodiazepines (11.8%, n=67), opioids (8.5%, n=48), and other substances in less than 2% each (Figure 1). The acute poisoning cases involved a single substance of abuse in 451 cases (79.4%), two substances in 74 cases (13%), and three or more substances in 43 cases (7.6%).
The acute poisoning events occurred in 37 (6.5%) cases in the patient's home, 31 (5.5%) cases in someone else's residence, and 127 (22.4%) cases in public places. In 65.7% of cases (n=373), the location of the poisoning was not specified.
A decrease in annual admissions was noted (R² = 0.44), but the proportion of these patients among all acute poisoning cases remained consistent throughout the study period. The frequency of the involved substances remained constant throughout the study period (Figure 2), except for benzodiazepines, which showed higher-than-expected incidences in 2022 (z=2.53), and amphetamine poisoning, which exhibited a trend of increasing incidence over time (χ2(1)=4.45; p=0.03).
The age distribution of the patients ranged from 11 to 18 years, with a mean age of 15.55 years (SD = 1.38) for the overall cohort. The ages of the patients significantly varied depending on the involved substance (p = 0.01), demonstrating that those who had heroin poisoning were younger, while those with amphetamine or cocaine poisoning were older. Notably, concurrent ethanol use, along with substance abuse, was significantly more common in female patients (z = 3.51; χ2 = 25.27; p < 0.001).
The overall cohort comprised a predominantly male population (65%; n=369), reflecting a 2:1 male-to-female ratio. Nevertheless, there were notable variations in sex distribution among the substances involved (Figure 3). For instance, NPS poisoning demonstrated a higher prevalence in males (z=1.45), while benzodiazepines and amphetamines showed a higher prevalence in females (z=1.14 and z=2.40, respectively). An analysis of age by sex showed that female patients had a significantly lower mean age (15.28 years old; SD = 1.36) than their male counterparts (15.69 years old; SD = 1.36; p < 0.001).
Patients were predominantly from urban areas (69%; n = 392). However, the distribution of residence areas varied significantly depending on the incriminated substances (Figure 4). For instance, individuals who had been poisoned with cannabis (z=2.16) were predominantly from urban areas, whereas those who had been poisoned with NPSs (z=2.82), opioids (z=2.39), or barbiturates (z=1.63) were predominantly from rural areas.
Chronic substance abuse was identified in 280 cases, accounting for 49.3% of the total. Moreover, this issue was more frequently associated with heroin poisoning (z=1.90) and less frequently with NPS poisoning (z=-1.5; see Figure 5A). Out of all patients, 152 (26.8%) had documented psychiatric disorders, which were more frequently associated with antipsychotic poisoning (z=2.21; see Figure 5B). The presence of institutional care was observed in 114 (20.0%) patients, with this issue being more frequent in cases involving NPSs (z=1.76), heroin (z=2.48), and antiepileptic poisoning (z=2.65) and less frequent in cases of amphetamine poisoning (z=-2.41; see Figure 5C). Chronic substance use was significantly linked to both institutional care (z = 2.71; p < 0.001) and the presence of psychiatric disorders (z = 4.49; p < 0.001).
Ethanol co-ingestion was documented in 113 patients (19.9%) and was more frequently associated with amphetamine poisoning (z=2.45, see Figure 5D).
The substances of abuse most frequently incriminated in cases of acute poisoning were cannabis and NPSs. The results for patients poisoned with one of these substances are detailed in the next two subsections.

3.2. Cannabis Poisoning

Patients presenting with cannabis poisoning had a mean age of 15.66 years (SD=1.27), in accordance with the overall cohort. The sex distribution in the cannabis poisoning subgroup was 2:1 male-to-female, which aligned with the sex distribution observed in the overall cohort (Figure 3). In addition, there was a predominance of cases from urban areas (z=2.16; Figure 4) when analysing the distribution of patients by area of residence.
Temporal analysis revealed a constant distribution of cannabis poisoning cases over the study period, with no significant trend (χ2(5)=8.66, p=0.12). However, in 2022, the frequency of cannabis poisoning was lower than the expected distribution for this particular year (z=-1.48; Figure 2).
The observed occurrence of cannabis poisoning in institutionalized patients, chronic drug users, and the alcohol co-exposure group was consistent with the distribution of cases in the study population. By contrast, the observed frequency of cannabis poisoning cases among patients with a documented psychiatric history was lower than expected based on the overall distribution of cases in our cohort (z=-1.17; Figure 5B).

3.3. NPS poisoning

An analysis of NPS poisoning cases among adolescents revealed a mean age of 15.39 years (SD=1.42), reflecting the age distribution of the cohort. The male-to-female ratio in NPS poisoning cases was 2.7:1, indicating a higher prevalence in males than females (z=1.45, Figure 3). Furthermore, patients from rural areas were overrepresented, with a frequency that was higher than expected (z=2.82; Figure 4).
The annual occurrence of NPS poisoning remained consistent throughout the study period (χ2(5)=6.99; p=0.22). However, a significant trend towards a decrease in frequency over time was observed (χ2(1)=5.39; p=0.02). This trend peaked in 2022, when the lowest number of cases was recorded (z=-1.78; see Figure 2).
NPS poisoning was observed more often than expected in institutionalized patients (z=1.76; Figure 5C) and in those with a documented psychiatric history (z=1.48; Figure 5B). By contrast, it occurred less frequently than expected among chronic abusers (z=-1.5; Figure 5A). Furthermore, co-exposure to ethanol alongside NPS poisoning occurred less commonly than anticipated (z=-1.27; Figure 5D).

4. Discussion

4.1. Patient Characteristics and Poisoning Circumstances

This study included 568 adolescents, mostly male (65%), which is in line with the literature and similar to the gender distribution observed in adult populations [12,13,14,15]. Most patients (69%) were from urban areas, with a mean age of 15.55 years, similar to previous findings [16,17]. Female patients presented at a significantly younger age than males, suggesting different behavioural patterns or social pressures influencing substance use initiation between these sexes. This consistent gender disparity in age at presentation has been documented in the literature [17,18]. Chronic substance use was significantly associated with institutional care and psychiatric disorders, highlighting the vulnerability of youth in institutionalized settings and those with mental health issues. A significant proportion of the cohort (26.8%) had documented psychiatric disorders, a co-occurrence well documented in the existing literature, underscoring the need for integrated care addressing both substance use and mental health [12,19,20]. Additionally, 20% of patients received institutional care, reinforcing the link between substance use and institutional care [13]. These findings emphasize the need for targeted interventions for institutionalized youth and those with psychiatric disorders.
Cannabis was the most involved substance in acute poisoning cases (45.6%), followed by new psychoactive substances (38.9%), benzodiazepines (11.8%), and opioids (8.5%), aligning with the European Monitoring Centre for Drugs and Drug Addiction's 2023 report [7]. The Romanian Observatory for Drugs and Drug Addiction's 2022 national report similarly highlighted NPSs and cannabis as the most used substances, and the American National Center for Drug Abuse Statistics' 2023 report noted cannabis as the most used substance, followed by opioids and LSD [8,21,22]. The high prevalence of cannabis and NPSs in our cohort is consistent with broader epidemiological trends showing increasing use of these substances among adolescents [23]. Age variations in substance use may indicate differences in accessibility, social acceptability, and risk perception, necessitating targeted prevention strategies tailored to specific adolescent groups.
Most poisoning incidents involved a single substance, but 13% involved two substances, and 7.6% involved three or more, indicating significant polysubstance use risk. Ethanol co-ingestion occurred in 19.9% of cases, with a gender difference: females were more likely to consume ethanol with other substances, suggesting different usage patterns influenced by social or behavioural factors. No significant link was found between ethanol co-ingestion and residence area, indicating widespread behaviour across environments. The clinical impact of alcohol co-ingestion along with other substances is well documented in the literature, though gender distribution data are scarce [24,25,26,27,28].
Despite a decrease in admissions per year, the proportion of acute poisoning cases among all admissions remained stable, suggesting persistent underlying issues. The lack of significant monthly admission trends suggests that acute poisoning is a constant concern rather than seasonal. However, seasonality has been noted in substance abuse-related deaths in England and Wales and in U.S. adolescent alcohol and drug use [29,30].
The majority of the poisoning incidents occurred in unknown locations, with many happening in public places, complicating monitoring and prevention efforts. Although the literature on the location of substance abuse incidents is limited, a 2020 Canadian paediatric hospital study reported that cannabis poisonings often occur in private residences [31].

4.2. Cannabis Poisoning

The present study provides a comprehensive analysis of cannabis poisoning among adolescents, examining demographic, geographic patterns, temporal trends, and associated characteristics. The mean age of the patients was 15.66 years, reflecting the overall cohort and the literature, highlighting mid-adolescents' vulnerability to cannabis-related harm during crucial developmental stages [32,33]. The sex distribution within the cannabis poisoning subgroup showed a 2:1 male-to-female ratio, consistent with the overall cohort and broader trends in adolescent substance use, where males are more prone to risk-taking behaviours [34,35,36,37]. Understanding these gender differences is crucial for developing targeted prevention and intervention strategies. Another noteworthy finding was that cannabis poisoning cases were more prevalent in urban areas, aligning with Canadian studies reporting higher rates in urban centres due to the greater availability of cannabis products in cities [38,39]. Unexpectedly, cannabis poisoning frequency among patients with documented psychiatric histories was lower than expected, contrasting with studies reporting higher substance use among those with psychiatric disorders [40,41].
No significant temporal trend in cannabis poisonings was identified, except for a slight decrease in 2022. This contrasts with North America, where cannabis poisoning has increased post-legalization, especially with edible cannabis products mistaken for food by children [42,43]. In Romania, where cannabis remains illegal, the stable incidence may be due to strict enforcement and limited availability, unlike in Canada and some U.S. states, where legalization has increased access and poisoning incidents, highlighting the impact of legal frameworks on substance use patterns. The slight decrease in 2022 may indicate effective law enforcement, public health campaigns, or shifts in youth behaviour during the COVID-19 pandemic [44,45]. Conversely, North America's post-legalization increase shows the complexities of drug policy changes, where increased availability and perceived safety lead to higher use and accidental poisonings, particularly with edibles [46].

4.3. NPS Poisoning

The results for NPSs revealed important trends. A mean age of 15.39 years and a male-to-female ratio of 2.7:1 indicate a higher NPS poisoning prevalence among males, consistent with global patterns [7,23,47]. Our finding that NPS poisoning is more common in rural areas contrasts with trends typically observed for other substances, which often show higher incidences in urban areas. This rural predominance could be due to several factors, including differences in availability, socioeconomic dynamics, or reporting practices in rural versus urban areas.
Internationally, the NPS landscape has evolved, with the EMCDDA noting fewer new substances in 2022, likely owing to tighter regulations [7]. Similarly, the United Nations Office on Drugs and Crime has reported that 2022 saw the lowest number of new NPSs reported in over a decade. This reduction could indicate effective international and national efforts to control the proliferation of these substances [47]. Our study showed a significant decrease in NPS poisoning cases over time, with the lowest number of cases recorded in 2022. This decline aligns with international trends, indicating that stricter regulations are effective. The European Drug Report 2023 highlights legislative measures reducing new psychoactive substances entering the market [7].
The high occurrence of NPS poisonings among institutionalized patients and those with psychiatric histories in our study highlights their vulnerability, consistent with other regions where mental health issues increase substance abuse risk [47]. By contrast, lower NPS poisoning rates among chronic abusers and those co-exposed to ethanol suggest different usage patterns or substance preferences.

4.4. Benzodiazepine Poisoning

The analysis of acute benzodiazepine poisonings in Romanian adolescents revealed a mean age of 15.63 years, with a higher prevalence among females (male-to-female ratio of 1.3:1). Over the study period, the frequency of benzodiazepine poisonings showed significant variability, with a notable increase in cases in 2022.
Acute benzodiazepine poisonings revealed a mean age of 15.63 years and a higher prevalence among females (male-to-female ratio of 1.3:1). Benzodiazepine poisoning cases increased notably in 2022. This trend mirrors global patterns, with rising misuse and poisonings involving benzodiazepines and especially opioids. The CDC notes increased overdoses involving illicit benzodiazepines like etizolam and flualprazolam [48,49]. In Europe, the EMCDDA also reports concerns about benzodiazepine misuse, especially with other substances [7,50]. The trend of increasing benzodiazepine-related poisonings mirrors patterns observed in Romania, with fluctuations in prevalence likely influenced by changes in drug availability and public health measures. The increased benzodiazepine poisonings among females in our study align with broader observations that young females more often misuse prescription medications, linked to higher anxiety and depression rates, underscoring the need for targeted interventions [48]. The spike in benzodiazepine poisonings in 2022 may reflect the COVID-19 pandemic's impact. This period saw rising mental health issues and medication misuse. Increased benzodiazepine prescriptions during the pandemic support this, as individuals sought to manage stress and anxiety, reflecting a broader trend of heightened medication use [51,52]. Furthermore, an editorial in Frontiers in Psychiatry discusses how the COVID-19 pandemic led to increased benzodiazepine use, supported by a prospective observational study in Catalonia that recorded higher benzodiazepine prescriptions from March 2020 to December 2021 compared with the previous two years [53]. This increase is indicative of a global trend where the pandemic exacerbated mental health issues, leading to greater reliance on medications for relief.

4.5. Amphetamine Poisoning

The analysis of acute amphetamine poisoning among adolescents revealed a mean age of 16 years and a higher prevalence among females (male-to-female ratio of 0.7:1). This contrasts with U.S. data but aligns with increasing use among European females [7,54]. Globally, trends in amphetamine use and poisoning have been inconsistent. U.S. data show rising amphetamine-related emergency visits due to both illicit and prescription misuse, such as with Adderall and Ritalin [55]. The results also revealed a consistent incidence of amphetamine poisoning over the study period, peaking in 2020, reflecting increased pandemic-related stress and drug use. The increased stress, social isolation, and changes in drug availability during the pandemic contributed to increased amphetamine use and poisoning. The National Institute on Drug Abuse (NIDA) reported that drug overdoses, including those involving amphetamines, increased during the pandemic owing to factors such as increased stress and decreased access to treatment [56]. Amphetamine poisoning was less common among institutionalized patients but often involved co-exposure to ethanol. The significant association with co-exposure to ethanol is consistent with other research indicating that polysubstance use, particularly with alcohol, is common among amphetamine users [57].

4.6. Opioids Poisoning

The findings regarding acute opioid poisonings provides valuable insights into the demographic and geographic patterns of these incidents. The mean age of patients with acute intentional heroin poisoning was 14.78 years, which is slightly lower than the overall cohort's mean age but consistent with international data [58,59]. Heroin poisoning was more prevalent among individuals in institutional care, with chronic substance abuse, and in rural areas, mirroring the U.S. literature [60,61]. No significant trend was observed in the prevalence of heroin poisoning over the study period. The consistent prevalence of opioid poisonings over the study period, without a significant upward or downward trend, contrasts with the escalating opioid crisis observed in North America [58,59,62,63]. This stability could be attributable to the implementation of effective regulatory measures, differences in drug availability, or variations in reporting practices between regions.

4.7. Barbiturate Poisoning

The analysis of barbiturate poisonings revealed several key findings. Barbiturate poisonings were more frequent among patients from rural areas and less common in those with co-exposure to ethanol. The temporal trends exhibited variability, with peaks in 2017 and 2018 and fewer cases in subsequent years.
Barbiturate poisonings were more frequent in rural areas and less common with ethanol co-exposure, peaking in 2017 and 2018. Globally, barbiturate use has declined due to the availability of safer alternatives like benzodiazepines. However, barbiturate toxicity remains significant, especially in intentional overdoses and suicides. Australian data indicate declining hospitalizations but rising deaths from barbiturate misuse [64].

4.8. Cocaine Poisoning

The mean age of patients with acute intentional cocaine poisoning in the study was 16.45 years; this was slightly higher than the overall cohort. This finding aligns with data from the United States, in which adolescent cocaine use is commonly observed in older adolescents [65]. The low incidence in rural areas and institutionalized patients suggests that environmental factors influence cocaine use. Co-exposure to ethanol is common, increasing health risks [66]. The unusual spike in cocaine poisonings in 2021 may align with disruptions caused by the COVID-19 pandemic, which impacted drug availability and use patterns across various regions [67].

4.9. MDMA Poisoning

The patterns of MDMA poisoning exhibited annual fluctuations, peaking in 2020. This indicates variability in MDMA use or reporting within this population. Notably, the occurrence of MDMA poisoning was lower among patients in institutional care. Lower incidence in institutional care suggests variability in use or reporting, but further research is needed regarding this matter. Globally, MDMA remains prevalent in urban nightlife areas. The European Drug Report 2023 and U.S. data indicate fluctuating MDMA use and poisonings [7,68].

4.10. Antipsychotic Medication Poisoning

The results on acute intentional poisoning with antipsychotic medications in adolescents reveal significant insights. There was a higher frequency of antipsychotic poisoning among patients with a psychiatric history, while co-exposure to ethanol was less frequent. The literature on concurrent alcohol and antipsychotic abuse in adolescents is scarce, indicating a need for further research. A study by Kaguelidou et al. (2020) reports increasing antipsychotic use in children and adolescents in Europe, raising the risk of poisoning [69]. Our findings align with Predescu et al. (2023), who found psychiatric disorders are significant risk factors for deliberate self-poisoning in adolescents [70].

4.11. LSD Poisoning

LSD poisoning in adolescents showed a low incidence, with one or two cases annually, consistent with the literature [71]. A particularly noteworthy finding in our study is the lower-than-expected prevalence of LSD poisoning among patients in institutional care. The literature on the correlation between LSD poisoning and institutional care settings is limited, indicating an area for further research.

4.12. Antiepileptic Drug (AED) Poisoning

AED poisoning is a significant concern owing to this drug type’s availability for chronic conditions like epilepsy. Our study found a higher incidence among institutionalized patients, warranting further examination of contributing factors. Globally, paediatric AED poisonings have risen over the last decade [72].

4.13. Poisoning with Other Substances

Finally, eight instances of poisoning involved less-common substances. Four cases involved glue inhalation, specifically "prenandez," highlighting concerns about its accessibility and neurotoxic effects [73]. The other four cases involved ingesting toxic plant parts (Datura stramonium and Atropa belladonna). Both plants contain potent psychoactive alkaloids that can cause severe neuropsychiatric and cardiotoxic effects. These findings are consistent with reports in the literature that emphasize the dangers of plant-based intoxications, especially in regions where such plants are readily accessible [74].

4.14. Strengths and Limitations

This study’s strengths include its multicentre design, including data from multiple paediatric poison centres, which provided a comprehensive overview of adolescent poisoning incidents. The six-year study duration allowed for a detailed examination of temporal trends and substance use patterns among adolescents. This study is notable for its valuable epidemiological insights into associations between chronic substance use, type of care, psychiatric disorders, substances involved in poisonings, and socio-clinical factors. It addresses the lack of literature on this age group, shedding light on the relationships between adolescent substance abuse and clinical and social determinants.
This study's limitations include its exclusive use of data from three paediatric poison centres in specific regions of Romania, potentially limiting the applicability of the findings to other populations or regions. Data completeness and accuracy challenges in retrospective designs may lead to inconsistencies. The observational nature introduces the possibility of inadequately addressing confounding variables such as socioeconomic status, family dynamics, and medical histories. Additionally, focusing on adolescents treated at paediatric poison centres might introduce selection bias by excluding less severe cases managed elsewhere.

5. Conclusions

Poisoning with substances of abuse remains a persistent public health concern, with a steady number of cases reported annually. This study highlights that cannabis and NPSs are among the most frequently involved substances in acute intentional poisoning incidents. The demographic and clinical profiles of adolescents affected by these substances vary significantly. Cannabis poisoning is more prevalent in urban areas and less frequently associated with a psychiatric history. Conversely, NPS poisoning is more common in rural areas and among patients in institutional care, and it is significantly associated with a psychiatric history. These findings underscore the need for targeted prevention and intervention strategies tailored to the specific risk profiles associated with each substance.

Author Contributions

Conceptualization, T.A.T., D.L.B., C.E.U., and G.V.N.; methodology, T.A.T., A.L., C.J., A.M.B., M.G., M.D.C., C.D.C., D.L.B., C.M.M., C.E.U., and G.V.N.; software, A.L., A.C.S., L.M.G., and A.I.V.; validation, T.A.T., C.J., A.M.B., M.G., M.D.C., C.D.C., D.L.B., C.M.M., C.E.U., and G V.N.; formal analysis, A.L., A.R.G., A.C.S., L.M.G., and A.I.V.; investigation, A.L., A.R.G., A.C.S., L.M.G., and A.I.V.; resources, T.A.T., C.J., A.M.B., M.G., C.E.U., and G.V.N.; data curation, T.A.T., A.L., C.J., A.M.B., M.G., M.D.C., C.D.C., D.L.B., C.M.M., C.E.U., and G.V.N.; writing—original draft preparation, T.A.T., A.L., A.R.G., A.C.S., L.M.G., and A.I.V.; writing—review and editing, C.J., A.M.B., M.G., M.D.C., C.D.C., D.L.B., C.M.M., C.E.U., and G.V.N.; visualization, A.L., L.M.G., and A.I.V.; supervision, G.V.N.; project administration, T.A.T. and G.V.N.; All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study adhered to the ethical principles outlined in the Declaration of Helsinki and was approved by the Ethics Committee of the hospital (Approval No. 11358, dated 18 March 2024).

Informed Consent Statement

All guardians of the patients included in the study provided informed consent for their participation.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request due to privacy concerns.

Acknowledgements

Publication of this paper was supported by the University of Medicine and Pharmacy “Carol Davila” through the institutional program Publish not Perish.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Wang GS, Hoyte C. Common Substances of Abuse. Pediatr Rev. 2018;39(8):403-414. [CrossRef]
  2. Nath A, Choudhari SG, Dakhode SU, Rannaware A, Gaidhane AM. Substance Abuse Amongst Adolescents: An Issue of Public Health Significance. Cureus. 2022;14(11):e31193. [CrossRef]
  3. Wu P, Hoven CW, Fuller CJ. Factors associated with adolescents receiving drug treatment: findings from the National Household Survey on Drug Abuse. J Behav Health Serv Res. 2003;30(2):190-201. [CrossRef]
  4. Ciucă Anghel DM, Nițescu GV, Tiron AT, Guțu CM, Baconi DL. Understanding the Mechanisms of Action and Effects of Drugs of Abuse. Molecules. 2023;28(13):4969. [CrossRef]
  5. Marino EN, Jha MK, Minhajuddin A, et al. Problematic substance use in depressed adolescents: Prevalence and clinical correlates. Addict Behav Rep. 2024;19:100539. [CrossRef]
  6. Ozakar Akca S, Turan Pinar A. Substance Abuse and Its Prevention in Adolescents. Addicta. 2023;10(1):86-92. [CrossRef]
  7. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2023: Trends and Developments. 2023. Available at: https://www.emcdda.europa.eu/publications/european-drug-report/2023/drug-situation-in-europe-up-to-2023_en. Accessed in May 2024.
  8. The Romanian Drug and Drug Addiction Observatory. The National Report on the situation of drugs in Romania. 2022. Available at: https://ana.gov.ro/wp-content/uploads/2023/02/RN_2022.pdf. Accessed in May 2024.
  9. Yates F. Contingency tables involving small numbers and the χ2 test. Suppl. J. R. Stat. Soc. 1934;1:217. [CrossRef]
  10. Cochran WG. Some methods for strengthening the common χ2 tests. Biometrics. 1954;10:417. [CrossRef]
  11. Armitage P. Tests for Linear Trends in Proportions and Frequencies. Biometrics. 1955;11(3):375. [CrossRef]
  12. Kloos A, Weller RA, Chan R, Weller EB. Gender differences in adolescent substance abuse. Curr Psychiatry Rep. 2009;11(2):120-126. [CrossRef]
  13. Pawer S, Rajabali F, Zheng A, et al. Socioeconomic factors and substances involved in poisoning-related emergency department visits in British Columbia, Canada. Health Promot Chronic Dis Prev Can. 2021;41(7-8):211-221. [CrossRef]
  14. Noseda R, Franchi M, Pagnamenta A, et al. Determinants of Admission to Critical Care Following Acute Recreational Drug Toxicity: A Euro-DEN Plus Study. J Clin Med. 2023;12(18):5970. [CrossRef]
  15. Miró Ò, Burillo-Putze G, Schmid Y, et al. Severity of emergency department presentations due to acute drug toxicity in Europe: a longitudinal analysis over a 6-year period (2014-2019) stratified by sex. Eur J Emerg Med. 2023;30(1):21-31. [CrossRef]
  16. Bracken BK, Rodolico J, Hill KP. Sex, age, and progression of drug use in adolescents admitted for substance use disorder treatment in the northeastern United States: comparison with a national survey. Subst Abus. 2013;34(3):263-272. [CrossRef]
  17. Alcover KC, Thompson CL. Patterns of Mean Age at Drug Use Initiation Among Adolescents and Emerging Adults, 2004-2017. JAMA Pediatr. 2020;174(7):725-727. [CrossRef]
  18. Agbese E, Stein BD, Druss BG, Dick AW, Pacula RL, Leslie DL. Mental Health Conditions and Substance Use Disorders Among Youth Subsequently Diagnosed With Opioid Use Disorder or Opioid Poisoning. J Addict Med. 2022;16(3):357-359. [CrossRef]
  19. Torrens M, Gilchrist G, Domingo-Salvany A; psyCoBarcelona Group. Psychiatric comorbidity in illicit drug users: substance-induced versus independent disorders. Drug Alcohol Depend. 2011;113(2-3):147-156. [CrossRef]
  20. Sheidow AJ, McCart M, Zajac K, Davis M. Prevalence and impact of substance use among emerging adults with serious mental health conditions. Psychiatr Rehabil J. 2012;35(3):235-243. [CrossRef]
  21. National Center for Drug Abuse Statistics. Drug Abuse Statistics 2023. Available at: https://drugabusestatistics.org. Accessed in May 2024.
  22. Waters ML, Dargan PI, Yates C, et al. Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020. Clin Toxicol (Phila). 2024;62(6):378-384. [CrossRef]
  23. Crulli B, Dines AM, Blanco G, et al. Novel psychoactive substances-related presentations to the emergency departments of the European drug emergencies network plus (Euro-DEN plus) over the six-year period 2014-2019. Clin Toxicol (Phila). 2022;60(12):1318-1327. [CrossRef]
  24. Supervía A, Ibrahim-Achi D, Miró Ò, et al. Impact of co-ingestion of ethanol on the clinical symptomatology and severity of patients attended in the emergency department for recreational drug toxicity. Am J Emerg Med. 2021;50:422-427. [CrossRef]
  25. Ford JA, McCabe SE, Schepis TS. Prescription Drug Misuse with Alcohol Coingestion among US Adolescents: Youth Experiences, Health-related Factors, and Other Substance Use Behaviors. J Addict Med. 2023;17(4):379-386. [CrossRef]
  26. de Veld L, Wolberink IM, van Hoof JJ, van der Lely N. The role of tobacco smoking and illicit drug use in adolescent acute alcohol intoxication. BMC Pediatr. 2021;21(1):233. [CrossRef]
  27. Demir AÇ, Dönmez YE, Kartalcı G, Bingöl ME, Temelli G, Özcan Ö. The relationship between smoking, alcohol, and substance abuse and psychiatric diseases among adolescents treated in a child and adolescent psychiatry inpatient unit. Turk J Pediatr. 2022;64(5):816-824. [CrossRef]
  28. Ciucă Anghel DM, Vlasceanu AM, Tudor G, Ciobanu AM, Stan M, Nitescu GV, Florou D, Tsatsakis AM, Baconi DL. Characterization of various groups of drugs users. Highlights on legal highs users. Farmacia. 2023;71(1):18–28. [CrossRef]
  29. Lewer D, Brothers TD, Gasparrini A, Strang J. Seasonal, weekly and other cyclical patterns in deaths due to drug poisoning in England and Wales. Addiction. 2023;118(8):1596-1601. [CrossRef]
  30. Huang LX, Schildhaus S, Wright D. Seasonality of substance use: National Household Survey on Drug Abuse 1992–96 (OAS working paper). 1999. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies.
  31. Cheng P, Zagaran A, Rajabali F, Turcotte K, Babul S. Setting the baseline: a description of cannabis poisonings at a Canadian pediatric hospital prior to the legalization of recreational cannabis. Health Promot Chronic Dis Prev Can. 2020;40(5-6):193-200. [CrossRef]
  32. Knapp AA, Lee DC, Borodovsky JT, Auty SG, Gabrielli J, Budney AJ. Emerging Trends in Cannabis Administration Among Adolescent Cannabis Users. J Adolesc Health. 2019;64(4):487-493. [CrossRef]
  33. Tims FM, Dennis ML, Hamilton N, et al. Characteristics and problems of 600 adolescent cannabis abusers in outpatient treatment. Addiction. 2002;97 Suppl 1:46-57. [CrossRef]
  34. Osborne A, James PB, Olorunsaiye CZ, Bangura C, Lebbie A. Cannabis use and its psychosocial correlates among school-going adolescents in Sierra Leone. BMC Public Health. 2024;24(1):986. [CrossRef]
  35. Hughes AR, Grusing S, Lin A, et al. Trends in intentional abuse and misuse ingestions in school-aged children and adolescents reported to US poison centers from 2000-2020. Clin Toxicol (Phila). 2023;61(1):64-71. [CrossRef]
  36. Cohen N, Mathew M, Brent J, et al. Severe outcomes following pediatric cannabis intoxication: a prospective cohort study of an international toxicology surveillance registry. Clin Toxicol (Phila). 2023;61(8):591-598. [CrossRef]
  37. Schmid Y, Galicia M, Vogt SB, et al. Differences in clinical features associated with cannabis intoxication in presentations to European emergency departments according to patient age and sex. Clin Toxicol (Phila). 2022;60(8):912-919. [CrossRef]
  38. Varin M, Champagne A, Venugopal J, et al. Trends in cannabis-related emergency department visits and hospitalizations among children aged 0-11 years in Canada from 2015 to 2021: spotlight on cannabis edibles. BMC Public Health. 2023;23(1):2067. [CrossRef]
  39. Tweet MS, Nemanich A, Wahl M. Pediatric Edible Cannabis Exposures and Acute Toxicity: 2017-2021. Pediatrics. 2023;151(2):e2022057761. [CrossRef]
  40. Davis GP, Compton MT, Wang S, Levin FR, Blanco C. Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr Res. 2013;151(1-3):197-202. [CrossRef]
  41. Buckner JD, Heimberg RG, Schneier FR, Liu SM, Wang S, Blanco C. The relationship between cannabis use disorders and social anxiety disorder in the National Epidemiological Study of Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2012;124(1-2):128-134. [CrossRef]
  42. Allaf S, Lim JS, Buckley NA, Cairns R. The impact of cannabis legalization and decriminalization on acute poisoning: A systematic review. Addiction. 2023;118(12):2252-2274. [CrossRef]
  43. Laudone TW, Leonard JB, Hines EQ, Seung H, Klein-Schwartz W. Changes in unintentional cannabis exposures in children 6 months to 5 years reported to United States poison centers during the first nine months of the coronavirus-19 pandemic. Clin Toxicol (Phila). 2022;60(9):1029-1031. [CrossRef]
  44. Compton WM, Flannagan KSJ, Silveira ML, et al. Tobacco, Alcohol, Cannabis, and Other Drug Use in the US Before and During the Early Phase of the COVID-19 Pandemic. JAMA Netw Open. 2023;6(1):e2254566. [CrossRef]
  45. Merrill JE, Stevens AK, Jackson KM, White HR. Changes in Cannabis Consumption Among College Students During COVID-19. J Stud Alcohol Drugs. 2022;83(1):55-63. [CrossRef]
  46. Roehler DR, Smith H 4th, Radhakrishnan L, et al. Cannabis-Involved Emergency Department Visits Among Persons Aged <25 Years Before and During the COVID-19 Pandemic - United States, 2019-2022. MMWR Morb Mortal Wkly Rep. 2023;72(28):758-765. [CrossRef]
  47. United Nations Office on Drugs and Crimes. Early Warning Advisory on New Psychoactive Substances. 2023. Available at: https://www.unodc.org/LSS/Announcement/Details/14abc955-499d-4f0c-b3c9-0bebe7b569cc. Accessed in May 2024.
  48. Liu S, O'Donnell J, Gladden RM, McGlone L, Chowdhury F. Trends in Nonfatal and Fatal Overdoses Involving Benzodiazepines - 38 States and the District of Columbia, 2019-2020. MMWR Morb Mortal Wkly Rep. 2021;70(34):1136-1141. [CrossRef]
  49. The Center for Forensic Science Research and Education. Trend Reports-NPS Benzodiazepines in the Untited States. 2024. Available at: https://www.cfsre.org/nps-discovery/trend-reports/nps-benzodiazepines/report/49?trend_type_id=1. Accessed in May 2024.
  50. Heier EC, Eyer F, Rabe C, et al. Clinical effect of ethanol co-use in patients with acute drug toxicity involving the use of central nervous system depressant recreational drugs. Eur J Emerg Med. 2022;29(4):291-300. [CrossRef]
  51. Kurvits K, Toompere K, Jaanson P, Uusküla A. The COVID-19 pandemic and the use of benzodiazepines and benzodiazepine-related drugs in Estonia: an interrupted time-series analysis. Child Adolesc Psychiatry Ment Health. 2024;18(1):66. [CrossRef]
  52. de Dios C, Fernandes BS, Whalen K, et al. Prescription fill patterns for benzodiazepine and opioid drugs during the COVID-19 pandemic in the United States. Drug Alcohol Depend. 2021;229(Pt A):109176. [CrossRef]
  53. Berro LF, Fidalgo TM, Rowlett JK, Tardelli VS. Editorial: Benzodiazepine addiction: from lab to street. Front Psychiatry. 2023;14:1287352. [CrossRef]
  54. Vivolo-Kantor AM, Hoots BE, Scholl L, et al. Nonfatal Drug Overdoses Treated in Emergency Departments - United States, 2016-2017. MMWR Morb Mortal Wkly Rep. 2020;69(13):371-376. [CrossRef]
  55. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network (DAWN) Releases. 2022. Available at: https://www.samhsa.gov/data/release/2022-drug-abuse-warning-network-dawn-releases. Accessed in May 2024.
  56. National Institute on Drug Abuse. COVID-19 and Substance Use. 2023. Available at: https://nida.nih.gov/research-topics/covid-19-substance-use. Accessed in May 2024.
  57. California Health Care Foundation. Substance Use Disorder in California: Almanac 2022. Available at: https://www.chcf.org/wp-content/uploads/2022/01/SubstanceUseDisorderAlmanac2022.pdf. Accessed in May 2024.
  58. Federal, provincial, and territorial Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid- and Stimulant-related Harms in Canada. Ottawa: Public Health Agency of Canada. 2024. Available at: https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/. Accessed in May 2024.
  59. Lee YK, Gold MS, Blum K, Thanos PK, Hanna C, Fuehrlein BS. Opioid use disorder: current trends and potential treatments. Front Public Health. 2024;11:1274719. [CrossRef]
  60. Lu A, Armstrong M, Alexander R, et al. Trends in pediatric prescription-opioid overdoses in U.S. emergency departments from 2008-2020: An epidemiologic study of pediatric opioid overdose ED visits. PLoS One. 2024;19(4):e0299163. [CrossRef]
  61. Gaither JR, Leventhal JM, Ryan SA, Camenga DR. National Trends in Hospitalizations for Opioid Poisonings Among Children and Adolescents, 1997 to 2012. JAMA Pediatr. 2016;170(12):1195-1201. [CrossRef]
  62. Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2024. Available at: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed in May 2024.
  63. Stan M, Burcea-Dragomirescu GTA, Vasiliu A, Ginghina O, Nitescu GV, Vlasceanu AM, Ciobanu AM, Baconi DL. Screening Method for the Detection of Dextromethorphan Abuse by HPTLC. Farmacia. 2022;70(6):1123–1131. [CrossRef]
  64. Darke S, Chrzanowska A, Campbell G, Zahra E, Lappin J. Barbiturate-related hospitalisations, drug treatment episodes, and deaths in Australia, 2000-2018. Med J Aust. 2022;216(4):194-198. [CrossRef]
  65. Schneider KE, Krawczyk N, Xuan Z, Johnson RM. Past 15-year trends in lifetime cocaine use among US high school students. Drug Alcohol Depend. 2018;183:69-72. [CrossRef]
  66. Morentin B, Meana JJ, Callado LF. Ethanol and illicit drugs acute use and abuse as risk factors for suicide: A case-control study based on forensic autopsies in the Basque Country, Spain. Span J Psychiatry Ment Health. 2023;16(2):109-115. [CrossRef]
  67. Mellos E, Paparrigopoulos T. Substance use during the COVID-19 pandemic: What is really happening?. Psychiatriki. 2022;33(1):17-20. [CrossRef]
  68. National Institute on Drug Abuse. What is the scope of MDMA use in the United States?. 2023. Available at: https://nida.nih.gov/publications/research-reports/mdma-ecstasy-abuse/what-is-the-scope-of-mdma-use-in-the-united-states. Accessed in May 2024.
  69. Kaguelidou F, Holstiege J, Schink T, et al. Use of antipsychotics in children and adolescents: a picture from the ARITMO population-based European cohort study. Epidemiol Psychiatr Sci. 2020;29:e117. [CrossRef]
  70. Predescu E, Calugar I, Bibu-Monus C, Sipos R. Trends and Prevalence of Hospital Admissions Related to Deliberate Self-Poisoning and Used Substances in Romanian Adolescents between 2016 and 2022. Children (Basel). 2023;10(5):790. [CrossRef]
  71. Engelgardt P, Krzyżanowski M, Borkowska-Sztachańska M, Wasilewska A, Ciucias M. Life time use of illicit substances among adolescents and young people hospitalized in psychiatric hospital. Sci Rep. 2023;13(1):1866. [CrossRef]
  72. Ferranti S, Grande E, Gaggiano C, Grosso S. Antiepileptic drugs: Role in paediatric poisoning. J Paediatr Child Health. 2018;54(5):475-479. [CrossRef]
  73. Lipari RN. Understanding Adolescent Inhalant Use. In: The CBHSQ Report. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); June 12, 2017.1-7.
  74. Nițescu GV, Grama A, Turcu T, et al. Epidemiology and Clinical Characteristics of Acute Plant Exposure in Patients Aged between 0 and 18 Years-A Six-Year Retrospective Study. Children (Basel). 2024;11(3):271. [CrossRef]
Preprints 112697 g001
Figure 1. The frequency of substances of abuse involved in acute intentional poisoning cases. Abbreviations: NPSs, new psychoactive substances; MDMA, methylenedioxymethamphetamine; LSD, lysergic acid diethylamide.
Figure 1. The frequency of substances of abuse involved in acute intentional poisoning cases. Abbreviations: NPSs, new psychoactive substances; MDMA, methylenedioxymethamphetamine; LSD, lysergic acid diethylamide.
Preprints 112697 g001
Preprints 112697 g002
Figure 2. The temporal trends of the substances of abuse involved in acute intentional poisoning cases. Abbreviations: NPSs, new psychoactive substances.
Figure 2. The temporal trends of the substances of abuse involved in acute intentional poisoning cases. Abbreviations: NPSs, new psychoactive substances.
Preprints 112697 g002
Preprints 112697 g003
Figure 3. The distribution of patient sex by the substances of abuse involved in acute intentional poisoning cases. Abbreviations: NPSs, new psychoactive substances; MDMA, methylenedioxymethamphetamine; LSD, lysergic acid diethylamide.
Figure 3. The distribution of patient sex by the substances of abuse involved in acute intentional poisoning cases. Abbreviations: NPSs, new psychoactive substances; MDMA, methylenedioxymethamphetamine; LSD, lysergic acid diethylamide.
Preprints 112697 g003
Preprints 112697 g004
Figure 4. The distribution of patient area of residence by the substances of abuse involved in acute intentional poisoning cases. Abbreviations: NPSs, new psychoactive substances; MDMA, methylenedioxymethamphetamine; LSD, lysergic acid diethylamide.
Figure 4. The distribution of patient area of residence by the substances of abuse involved in acute intentional poisoning cases. Abbreviations: NPSs, new psychoactive substances; MDMA, methylenedioxymethamphetamine; LSD, lysergic acid diethylamide.
Preprints 112697 g004
Preprints 112697 g005
Figure 5. A-D. The distribution of chronic substance abusers (A), patients with psychiatric disorders (B), patients receiving care in an institutional setting (C), and the co-ingestion of ethanol beverages (D) by the substances of abuse involved in acute intentional poisoning cases. Abbreviations: NPSs, new psychoactive substances; MDMA, methylenedioxymethamphetamine; LSD, lysergic acid diethylamide.
Figure 5. A-D. The distribution of chronic substance abusers (A), patients with psychiatric disorders (B), patients receiving care in an institutional setting (C), and the co-ingestion of ethanol beverages (D) by the substances of abuse involved in acute intentional poisoning cases. Abbreviations: NPSs, new psychoactive substances; MDMA, methylenedioxymethamphetamine; LSD, lysergic acid diethylamide.
Preprints 112697 g005
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated